8/10/2021 7:59:07 AM
IMV Announces Final Topline Results Of DeCidE1 Clinical Trial In Advanced Recurrent Ovarian Cancer
8/4/2021 8:33:42 AM
IMV: Frederic Ors Steps Down As CEO
7/15/2021 7:07:40 AM
IMV Prices Public Offering Of 14.3 Mln Units At $1.75/unit
5/12/2021 7:09:27 AM
IMV Inc. Q1 Net Loss $7.0 Mln Vs. Net Loss $7.2 Mln Last Year
12/28/2020 7:09:47 AM
IMV Reports Update On Development Of Its Vaccine Candidate, DPX-COVID-19
12/3/2020 7:31:30 AM
IMV Reports Updated Clinical And Translational Data From Phase 2
clinical Study Of DPX-Survivac
11/12/2020 7:29:10 AM
IMV Q3 Loss/Shr C$0.13 Vs Loss C$0.16 Last Year
11/9/2020 8:18:27 AM
IMV: T Cell Therapy Show 86% Objective Response Rate In Combination With Keytruda In PD-L1 Patients With R/r DLBCL
10/8/2020 7:11:31 AM
IMV Provides Updates On Vaccine Candidate, DPX-COVID-19
7/20/2020 7:08:41 AM
IMV Inc. Says Appoints Michael Bailey To Its Board
7/14/2020 7:40:18 AM
IMV Provides Further Details On COVID-19 Vaccine Program